Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences POC Diagnostics, Global Health-Viral Diseases 2017

Debra English's Biography



Debra English, Manager Biochemistry Applications, GVS North America

Debra English has been the manager of biochemistry applications at GVS North America for 5 years. In this role, she oversees lateral flow assay optimization and the transition process to manufacturing. Prior to this, she was a research scientist at Maine Manufacturing (2010 to 2012) and GE Healthcare Life Sciences (2008 to 2010) where she focused on quantifying cytokine levels in human serum/plasma using multiplexed cytokine protein microarrays assays. She was also a research and development scientist at Whatman and Schleicher and Schuell. Both these companies were known for membrane and filter papers used for sample collection, preparation and assay development. While at S&S, she was the lead scientist to develop antibody-enzyme conjugates used in colorimetric and chemiluminescent detection for membrane-based protein assays. Before entering the commercial world, she was a chemist in the Laboratory of Immunogenetics at the National Institute of Allergy and Infectious Diseases with the focus on cell surface glycoproteins of rabbit lymphocytes. She received a BS in biochemistry from Pennsylvania State University in 1977.

Debra English Image

Practices and Challenges During Assay Optimization and the Transition Process to Manufacturing For Lateral Flow Assay Device Development

Wednesday, 4 October 2017 at 09:00

Add to Calendar ▼2017-10-04 09:00:002017-10-04 10:00:00Europe/LondonPractices and Challenges During Assay Optimization and the Transition Process to Manufacturing For Lateral Flow Assay Device DevelopmentPOC Diagnostics, Global Health-Viral Diseases 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Lateral flow assays are deceptively simple, rapid, inexpensive diagnostic tests which are used in clinics as well as remote areas.  However, the iterative process to develop and optimize a “simple”, robust, easy-to-run, sensitive assay reveals the complexity of a LFA.  A lateral flow assay consists of 3 key categories:  (1) biological reagents and buffers, (2) pads/membranes to store, transport, capture or detect such reagents, and (3) the assembly of all components into one working device.  The use of an antibody pairing matrix, progressing from half stick to three quarter to a full stick format and transitioning as soon as possible from spiked buffer to real sample are practices used during assay optimization.  Further optimization occurs during the transition from lab bench to manufacturing scale.  Some real-life examples of optimization will be discussed during the talk.


Add to Calendar ▼2017-10-02 00:00:002017-10-04 00:00:00Europe/LondonPOC Diagnostics, Global Health-Viral Diseases 2017POC Diagnostics, Global Health-Viral Diseases 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com